Want to see HK:2359 full AI Analyst Report?
2359 Stock Chart & Stats
HK$157.40
-HK$0.20(-0.13%)
At close: 4:00 PM EDT
HK$157.40
-HK$0.20(-0.13%)
Day’s Range― - ―
52-Week RangeHK$96.70 - HK$204.60
Previous CloseN/A
Volume2.11M
Average Volume (3M)6.08M
Market Cap
HK$546.70B
Enterprise ValueHK$269.81K
Total Cash (Recent Filing)HK$46.63B
Total Debt (Recent Filing)HK$15.11B
Price to Earnings (P/E)21.5
Beta1.49
Next Earnings
Oct 28, 2026EPS Estimate
2.05Next Dividend Ex-DateN/A
Dividend Yield1.08%
Share Statistics
EPS (TTM)7.52
Shares Outstanding510,476,900
10 Day Avg. Volume5,559,442
30 Day Avg. Volume6,076,831
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.18
Price to Sales (P/S)5.57
P/FCF Ratio21.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$203.73Price Target Upside29.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)8.75
Revenue Forecast (FY)HK$69.55B
Bulls Say, Bears Say
Bulls Say
High And Durable ProfitabilitySustained gross and net margins near 52% and 40% indicate structural pricing power and operating leverage across services. High margins support reinvestment, buffer project cyclicality, and enable above-average returns even if revenue growth moderates.
Conservative Balance Sheet, Low LeverageLow debt-to-equity (~0.18) provides financial flexibility for capex, capacity expansion and M&A, and reduces default risk in downturns. A strong equity base supports long-term investments in facilities central to CRDMO competitiveness.
Integrated End-to-end CRDMO PlatformAn end-to-end CRDMO model encourages client stickiness and multi-service engagements as programs progress. Cross-selling across discovery, development and manufacturing supports higher lifetime customer value and steadier demand as compounds advance.
Bears Say
Revenue Growth Volatility And 2024 DipProject-based CRDMO revenues are naturally lumpy; the 2024 revenue dip highlights visibility challenges for planning and capacity utilization. Persistent volatility complicates forecasting, capital allocation and could weigh on sustained investment or hiring decisions.
Only Moderate Cash Conversion Of EarningsCash generation has improved but still trails reported earnings, meaning earnings quality is not fully matched by cash. Moderate cash conversion limits internal funding for big-capex or large strategic initiatives without tapping external financing.
Rising Absolute Debt Versus Prior PeriodsAn increase in absolute debt, even from low leverage, raises financing costs and reduces flexibility if it becomes a trend. Should margins or revenues weaken, higher debt levels could constrain growth investments or force more conservative capital deployment.
WuXi AppTec Co., Ltd. Class H News
2359 FAQ
What was WuXi AppTec Co., Ltd. Class H’s price range in the past 12 months?
WuXi AppTec Co., Ltd. Class H lowest stock price was HK$96.70 and its highest was HK$204.60 in the past 12 months.
What is WuXi AppTec Co., Ltd. Class H’s market cap?
WuXi AppTec Co., Ltd. Class H’s market cap is HK$546.70B.
When is WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date?
WuXi AppTec Co., Ltd. Class H’s upcoming earnings report date is Oct 28, 2026 which is in 74 days.
How were WuXi AppTec Co., Ltd. Class H’s earnings last quarter?
WuXi AppTec Co., Ltd. Class H released its earnings results on Aug 03, 2026. The company reported HK$2.532 earnings per share for the quarter, beating the consensus estimate of HK$1.82 by HK$0.712.
Is WuXi AppTec Co., Ltd. Class H overvalued?
According to Wall Street analysts WuXi AppTec Co., Ltd. Class H’s price is currently Undervalued.
Does WuXi AppTec Co., Ltd. Class H pay dividends?
WuXi AppTec Co., Ltd. Class H pays a Notavailable dividend of HK$0.589 which represents an annual dividend yield of 1.08%. See more information on WuXi AppTec Co., Ltd. Class H dividends here
What is WuXi AppTec Co., Ltd. Class H’s EPS estimate?
WuXi AppTec Co., Ltd. Class H’s EPS estimate is 2.05.
How many shares outstanding does WuXi AppTec Co., Ltd. Class H have?
WuXi AppTec Co., Ltd. Class H has 510,476,900 shares outstanding.
What happened to WuXi AppTec Co., Ltd. Class H’s price movement after its last earnings report?
WuXi AppTec Co., Ltd. Class H reported an EPS of HK$2.532 in its last earnings report, beating expectations of HK$1.82. Following the earnings report the stock price went up 1.369%.
Which hedge fund is a major shareholder of WuXi AppTec Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2359
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi AppTec Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$203.73 (29.44% Upside)
HK$203.73 (29.44% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.09%
12-Months-Change
Fundamentals
Return on Equity
1.08%
Trailing 12-Months
Asset Growth
46.32%
Trailing 12-Months
Company Description
WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. operates as an investment holding enterprise, delivering extensive research, development, and manufacturing services. These services primarily aid in the discovery, advancement, and production of small molecule pharmaceuticals, as well as sophisticated cell and gene therapies. The company maintains a global footprint, serving clients across the People's Republic of China, other Asian territories, the United States, Europe, and various international markets. Its operations are structured across six key segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. The firm's comprehensive offerings encompass contract research, development, and manufacturing organization (CRDMO) services, supporting new drug development from initial discovery phases all the way to commercial launch. This scope extends to diverse synthetic molecular types, including small molecules, oligonucleotides, peptides, and complex conjugates. Furthermore, WuXi AppTec provides biology services and solutions that facilitate projects from target identification to candidate selection and subsequent clinical progression. The company also offers integrated drug and medical device testing services, covering everything from preclinical assessments to clinical trials. An end-to-end solution is available to expedite the market entry of cell and gene therapies, alongside specialized drug discovery services for pharmaceutical and biotechnology clients, and full-spectrum clinical research support. WuXi AppTec Co., Ltd. was established in 2000 and its headquarters are located in Shanghai, People's Republic of China.
2359 Stock 12 Month Forecast
Average Price Target
HK$203.73
▲(29.44% Upside)
Technical Analysis
Genscript Biotech
―
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―